According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback